• Mashup Score: 1
    Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages - 2 year(s) ago

    The anaphylatoxin C5a is core effector of complement activation. C5a exerts potent proinflammatory and immunomodulatory actions through interacting with its C5a receptors, C5aR1 and C5aR2, modulating multiple signaling and functional activities of immune cells. Native C5a contains a large N -linked

    Source: The Journal of Immunology
    Categories: Allergy-Immunology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of J_Immunol
      J_Immunol

      From the Trent Woodruff lab at @UQ_News | Suggest using recombinant human #C5a should be paired with #C5aR1 inhibitors, or purified/synthetic human C5a to confirm relevant findings https://t.co/RmESi8bU8W #ReadTheJI #immunology #complement #innateimmunology #macrophage https://t.co/S3JswTwy23

  • Mashup Score: 3
    The complement C5a-C5aR1 GPCR axis in COVID-19 therapeutics - 4 year(s) ago

    The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.

    Source: Trends in Immunology
    Categories: Allergy-Immunology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TrendsImmuno
      TrendsImmuno

      New In Press Spotlight @TrendsImmuno on The #complement #C5a-#C5aR1 #GPCR axis in #COVID19 therapeutics, by Trent Woodruff & Arun Shukla, https://t.co/SsO9I0AwTj